A tumor-penetrating bicyclic peptide that delivers a toxic payload may have finally unlocked the therapeutic potential of targeting EphA2. According to phase I trial data, BT5528 yielded clinical responses in three patients with ovarian and urothelial cancers—without any of the toxicity issues that have plagued other EphA2-directed therapeutic candidates.

You do not currently have access to this content.